These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 30066852)

  • 41. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung.
    Igarashi T; Teramoto K; Ishida M; Hanaoka J; Daigo Y
    Oncol Rep; 2017 Oct; 38(4):2189-2196. PubMed ID: 28791392
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resveratrol attenuates the progress of liver fibrosis via the Akt/nuclear factor-κB pathways.
    Zhang H; Sun Q; Xu T; Hong L; Fu R; Wu J; Ding J
    Mol Med Rep; 2016 Jan; 13(1):224-30. PubMed ID: 26530037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
    Ayub A; Yip WK; Seow HF
    Biomed Pharmacother; 2015 Oct; 75():40-50. PubMed ID: 26463630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction.
    Dong B; Ding Y; Huang Q; Guan X
    Med Sci Monit; 2019 Jan; 25():500-515. PubMed ID: 30653481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Resveratrol attenuates TNBC lung metastasis by down-regulating PD-1 expression on pulmonary T cells and converting macrophages to M1 phenotype in a murine tumor model.
    Han X; Zhao N; Zhu W; Wang J; Liu B; Teng Y
    Cell Immunol; 2021 Oct; 368():104423. PubMed ID: 34399171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Using phage-assisted continuous evolution (PACE) to evolve human PD1.
    Ye X; Tu M; Piao M; Yang L; Zhou Z; Li Z; Lin M; Yang Z; Zuo Z
    Exp Cell Res; 2020 Nov; 396(1):112244. PubMed ID: 32860814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation.
    Chen Y; Huang Y; Lu X; Wang G; Chi P
    Oncol Rep; 2018 Dec; 40(6):3370-3380. PubMed ID: 30272332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic value of PDL1 expression in pancreatic cancer.
    Birnbaum DJ; Finetti P; Lopresti A; Gilabert M; Poizat F; Turrini O; Raoul JL; Delpero JR; Moutardier V; Birnbaum D; Mamessier E; Bertucci F
    Oncotarget; 2016 Nov; 7(44):71198-71210. PubMed ID: 27589570
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Piceatannol suppresses breast cancer cell invasion through the inhibition of MMP-9: involvement of PI3K/AKT and NF-κB pathways.
    Ko HS; Lee HJ; Kim SH; Lee EO
    J Agric Food Chem; 2012 Apr; 60(16):4083-9. PubMed ID: 22480333
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.
    Haile ST; Dalal SP; Clements V; Tamada K; Ostrand-Rosenberg S
    J Immunol; 2013 Sep; 191(5):2829-36. PubMed ID: 23918985
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
    Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
    Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
    Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.
    Tamura T; Ohira M; Tanaka H; Muguruma K; Toyokawa T; Kubo N; Sakurai K; Amano R; Kimura K; Shibutani M; Maeda K; Hirakawa K
    Anticancer Res; 2015 Oct; 35(10):5369-76. PubMed ID: 26408698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer.
    Zhou Q; Xiong W; Zhou X; Gao RS; Lin QF; Liu HY; Li JN; Tian XF
    Mol Med Rep; 2019 Nov; 20(5):4244-4252. PubMed ID: 31545446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
    Peng J; Hamanishi J; Matsumura N; Abiko K; Murat K; Baba T; Yamaguchi K; Horikawa N; Hosoe Y; Murphy SK; Konishi I; Mandai M
    Cancer Res; 2015 Dec; 75(23):5034-45. PubMed ID: 26573793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paclitaxel-induced transcriptional regulation of Fas signaling pathway is antagonized by dexamethasone.
    Crozier M; Porter LA
    Breast Cancer Res Treat; 2015 Nov; 154(1):33-44. PubMed ID: 26463651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Resveratrol 3-O-D-glucuronide and resveratrol 4'-O-D-glucuronide inhibit colon cancer cell growth: evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest.
    Polycarpou E; Meira LB; Carrington S; Tyrrell E; Modjtahedi H; Carew MA
    Mol Nutr Food Res; 2013 Oct; 57(10):1708-17. PubMed ID: 23650147
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.
    Gato-Cañas M; Zuazo M; Arasanz H; Ibañez-Vea M; Lorenzo L; Fernandez-Hinojal G; Vera R; Smerdou C; Martisova E; Arozarena I; Wellbrock C; Llopiz D; Ruiz M; Sarobe P; Breckpot K; Kochan G; Escors D
    Cell Rep; 2017 Aug; 20(8):1818-1829. PubMed ID: 28834746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.